Malcolm Brenner Appointed to Lead New Houston Methodist Center for Cell and Gene Therapy
HOUSTON – Malcolm Brenner, a physician-scientist renowned for his pioneering work in cell and gene therapy, has been appointed to lead the newly established Houston Methodist Center for Cell and Gene Therapy.
"Brenner is a pioneer in cell and gene therapy and is qualified to lead Houston Methodist's research in this field."
The center's mission is to consolidate scientists and clinicians from Houston Methodist’s academic research and clinical care settings, creating a unified pipeline to develop new therapies for a wide range of diseases.
A Collaborative Approach to Accelerate Discovery
The new center will adopt a collaborative framework designed to accelerate the translation of preclinical discoveries into clinical evaluation. It will focus on supporting the development of genetic and cellular therapies for both congenital and acquired conditions.
Jenny Chang, president and CEO of the Houston Methodist Academic Institute, praised the appointment, stating that Brenner’s "vision and leadership will advance their work."
Leadership and Structure
The center will house translational research scientists, physician-scientists, and dedicated support staff. Crucially, Brenner and his team will continue their long-standing collaborations with Baylor College of Medicine and Texas Children's Hospital.
A Proven Pioneer in the Field
Brenner holds professorships in pediatrics, medicine, molecular and human genetics, and translational biology at Baylor College of Medicine. His career has been instrumental in transforming cell and gene therapy into clinical treatments.
- Redefining Bone Marrow Transplants: Trained in both immunology and hematology, Brenner helped redefine bone marrow transplantation as a form of cell therapy.
- Engineering Immune Cells: He demonstrated that engineered immune cells could be used to treat infection and cancer.
- Clinical Potential: His research established the clinical potential of virus-specific T cells and gene-modified hematopoietic stem cells.
Global Impact and Recognition
Beyond his laboratory work, Brenner has contributed significantly to the global infrastructure for cell and gene therapy research. This includes involvement in scientific societies and the establishment of early standards for the field. He is a member of both the National Academy of Medicine and the National Academy of Inventors. He earned his medical degree and doctorate from the University of Cambridge.